Skip to navigation bar Skip to breadcrumbs Skip to page content
clear place holder
Envelope icon E-mail Updates Teal square Text size:  a A A

Breast Cancer: Medication Use to Reduce Risk

Release Date: September 2019

Recommendation Summary

PopulationRecommendationGrade
(What's This?)
Women at increased risk for breast cancer

The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.

B
Women not at increased risk for breast cancer

The USPSTF recommends against the routine use of risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, in women who are not at increased risk for breast cancer.

D

To read the recommendation statement in JAMA, select here.

To read the evidence summary in JAMA, select here.

See the Clinical Considerations section for additional information about risk assessment.

Related Information for Health Professionals

There is no related information for health professionals.

Clinical Summary

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice.

This summary is intended for use by primary care clinicians.

 
Current as of: September 2019

Internet Citation: Final Update Summary: Breast Cancer: Medication Use to Reduce Risk. U.S. Preventive Services Task Force. September 2019.
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-medications-for-risk-reduction1?ds=1&s=breast cancer

USPSTF Program Office   5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857